Spots Global Cancer Trial Database for A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies
Official Title: A Phase Ib Clinical Study of BBI608 for Adult Patients With Advanced, Refractory Hematologic Malignancies
Study ID: NCT02352558
Conditions
Study Description
Brief Summary: This is a multicenter, open label, Phase 1 dose-escalation study of BBI608 administered to patients with relapsed, refractory hematologic malignancies, including multiple myeloma, lymphoma, and others.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Rocky Mountain Cancer Centers, Denver, Colorado, United States
Indiana University, Indianapolis, Indiana, United States
West Clinic, Germantown, Tennessee, United States
Cancer Care Centers of South Texas, San Antonio, Texas, United States
Cancer Care Centers of South Texas - HOAST, San Antonio, Texas, United States
Virginia Cancer Specialists, P.C., Fairfax, Virginia, United States
Virginia Oncology Associates, Norfolk, Virginia, United States
Northwest Cancer Specialists, PC, Vancouver, Washington, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
